A surveillance network for meningococcal disease in Europe

FEMS Microbiology Reviews

Volumn 31, Issue 1, 2007, Pages 27-36

  Trotter, Caroline L ^a,f   Chandra, Manosree ^a   Cano, Rosa ^b   Larrauri, Amparo ^b   Ramsay, Mary E ^a   Brehony, Carina ^c   Jolley, Keith A ^c   Maiden, Martin C J ^c   Heuberger, Sigrid ^d   Frosch, Matthias ^e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^e Institute of Hygiene and Microbiology   (Germany)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Epidemiology; Europe; Neisseria meningitidis; Surveillance

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHILD HEALTH; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INCIDENCE; INTERNET; LABORATORY DIAGNOSIS; MENINGOCOCCOSIS; MOLECULAR EPIDEMIOLOGY; MORTALITY; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; PUBLIC HEALTH; REVIEW; VACCINATION;

DATABASES, GENETIC; EUROPE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; POPULATION SURVEILLANCE;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

EID: 33846110029     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2006.00060.x     Document Type: Review

References (26)

1. Aguilera JF, Perrocheau A, Meffre C, Hahne S & W135 Working Group (2002) Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 8: 761-767.
2. Alcala B, Arreaza L, Salcedo C, Uria MJ, De La Fuente L & Vazquez JA (2002) Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis 8: 1512-1514.
3. Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, Morris R, Cartwright K & Miller E (2002) Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 186: 1353-1357.
4. Brassier N, Lepoutre A, Guibourdenche M, Moyse C & Riou JY (1995) Meningococcal meningitis and meningococcemia: epidemiological study, France (1985-1991). Med Mal Infect 25: 584-593.
5. Brehony C, Jolley KA & Maiden MCJ (2006) Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31: DOI:1111/j.1574-6976.2006.00056.x
6. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM & van Derende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25: 79-80.
7. Gjini AB, Stuart JM, Cartwright K, Cohen J, Jacobs M, Nichols T, Ninis N, Prempeh H, Whitehouse A & Heyderman RS (2006) Quality of in-hospital care for adults with acute bacterial meningitis: a national retrospective survey. Q J Med 99: 761-769.
8. Hahne S, Handford S & Ramsay M (2002) W135 meningococcal carriage in Hajj pilgrims. Lancet 360: 2089-2090.
9. Iversen B & Aavitsland P (1996) Meningococcal disease in Norway 1992-1995. Epidemiology and fatality. Scand J Infect Dis 28: 253-259.
10. Jensen ES, Schonheyder HC, Lind I, Berthelsen L, Norgard B & Sorensen HT (2003) Neisseria meningitidis phenotypic markers and septicaemia, disease progress and case-fatality rate of meningococcal disease: a 20-year population-based historical follow-up study in a Danish cohort. J Med Microbiol 52: 173-179.
11. Larrauri A, Cano R, Garcia M & Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 4097-4100.
12. Lenglet A & Hernández Pezzi G (2006) Comparison of the European Union disease surveillance networks' websites. Eurosurveillance 11: 119-122.
13. Maiden MCJ & Stuart JMon behalf of the UK Meningococcal Carriage Group (2002) Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1830.
14. Miller E, Salisbury D & Ramsay M (2001) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20: S58-S67.
15. Noah N & Henderson B (1999) Surveillance of Bacterial Meningitis in Europe 1997/98. PHLS Communicable Disease Surveillance Centre, London.
16. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB & Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England. Br Med J 326: 365-366.
17. Rosenstein NE, Perkins BA, Stephens DS et al. (1999) The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180: 1894-1901.
18. Scholten RJPM, Bijlmer HA, Valkenburg HA & Dankert J (1994) Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 112: 115-124.
19. Spanjaard L, Bol P, de Marie S & Zanen HC (1987) Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83. Bull WHO 65: 861-868.
20. Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD & Stephens DS (1997) Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 94: 271-276.
21. Trotter CL & Edmunds WJ (2006) Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 26: 38-47.
22. Trotter CL, Fox AJ, Ramsay ME, Sadler F, Gray SJ, Mallard R & Kaczmarski EB (2002) Fatal outcome from meningococcal disease-an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol 51: 855-860.
23. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E & Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine four years after introduction. Lancet 364: 365-367.
24. Trotter CL, Gay NJ & Edmunds WJ (2005a) Dynamic models of meningococcal carriage, disease and the impact of serogroup C vaccination. Am J Epidemiol 162: 89-100.
25. Trotter CL, Samuelsson S, Perrocheau A, de Greeff S, de Melker H, Heuberger S & Ramsay ME (2005b) Ascertainment of meningococcal disease in Europe. Eurosurveillance monthly 10: 247-250.
26. Welte R, Trotter CL, Edmunds WJ, Postma M & Beutels P (2005) The role of economic modelling studies in vaccine decision making: focus on meningococcal c vaccination. Pharamcoeconomics 23: 855-874.